IP Library Granted Patent US 7,169,776
Granted Patent B2
US 7,169,776 · App. 11/040,612 · Granted Jan 30, 2007

Method of preparing alkylated salicylamides via a dicarboxylate intermediate

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,169,776
App. No.
11/040,612
Granted
Jan 30, 2007
Kind
B2
Abstract

The present invention relates to a method of preparing an alkylated salicylamide from a protected and activated salicylamide via a dicarboxylated salicylamide intermediate. The present invention also relates to dicarboxylic salicylamide delivery agent compounds for the delivery of active agents. Methods of administration are provided as well.

Claims (46)

1. A compound having the formula

wherein

R 1 , R 2 , R 3 , and R 4 are independently hydrogen; halogen; C 1 –C 4 alkoxy, optionally substituted with —OH or F; —OH; C 1 –C 4 alkyl, optionally substituted with —OH or F; —COOH; —OC(O)CH 3 ; —SO 3 H; nitrile; or —NR 9 R 10 ;

R 5 a protecting group;

R 6 is an activating group; or

R 5 and R 6 are combined to form a substituted or unsubstituted cyclic group;

R 7 is a linear or branched, C 1 –C 20 alkylene, alkenylene, or alkynylene;

R 7 is optionally substituted with C 1 –C 4 alkyl, C 1 –C 4 alkenyl, oxygen, nitrogen, sulfur, halogen, —OH, C 1 –C 4 alkoxy, aryl, heteraryl, or vinyl;

R 7 is optionally interrupted with aryl, heteroaryl, vinyl, oxygen, nitrogen, or sulfur;

R 8 and R 11 are independently C 1 –C 4 alkyl or C 1 –C 4 haloalkyl; and

R 9 and R 10 are independently hydrogen, C 1 –C 4 alkyl, or oxygen, and

wherein both carboxylate groups attached to R 7 in the formula above are attached to the end of the alkylene, alkenylene. or alkynylene R 7 chain.

2. A compound selected from

wherein

R 14 and R 15 are independently C 1 –C 4 alkyl; and

R 16 and R 17 are independently hydrogen, C 1 –C 4 alkyl, C 2 –C 4 alkenyl, or C 2 –C 4 alkynyl.

3. The compound of claim 2 , wherein Y is —CH 2 —.

4. The compound of claim 2 , wherein Y is —C(O)—.

5. The compound of claim 2 , wherein R 14 and R 15 are independently methyl or ethyl.

6. A compound having the formula

wherein

R 1 , R 2 , R 3 , and R 4 are independently hydrogen; halogen; C 1 –C 4 alkoxy, optionally substituted with —OH or F; —OH; C 1 –C 4 alkyl, optionally substituted with —OH or F; —COOH; —OC(O)CH 3 ; —SO 3 H; nitrile; or —NR 9 R 10 ;

R 7 is a linear or branched, C 1 –C 20 alkylene, alkenylene, or alkynylene;

R 7 is optionally substituted with C 1 –C 4 alkyl, C 1 –C 4 alkenyl, oxygen, nitrogen, sulfur, halogen, —OH, C 1 –C 4 alkoxy, aryl, heteraryl, or vinyl; and

R 7 is optionally interrupted with aryl, heteroaryl, vinyl, oxygen, nitrogen, or sulfur; and

R 9 and R 10 are independently hydrogen, C 1 –C 4 alkyl, or oxygen,

and wherein both carboxyl groups attached to R 7 in the formula above are attached to the end of the alkylene, alkenylene, or alkynylene R 7 chain,

or a salt thereof.

7. A composition comprising:

(A) an active agent; and

(B) at least one compound of claim 6 .

8. A dosage unit form comprising:

(A) the composition of claim 7 ; and

(B) (i) an excipient,

(ii) a dilutent,

(iii) a disintegrant,

(iv) a lubricant,

(v) a plasticizer,

(vi) a colorant,

(vi) a dosing vehicle, or

(vii) any combination thereof.

9. A method for administering a biologically-active agent to an animal in need of the agent, the method comprising administering orally to the animal the composition of claim 7 .

10. A method for preparing a composition comprising mixing:

(A) at least one active agent;

(B) the compound of claim 6 ; and

(C) optionally, a dosing vehicle.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2021
From: EMISPHERE TECHNOLOGIES, INC.
To: NOVO NORDISK NORTH AMERICA OPERATIONS A/S
Reel/Frame 056750/0169 →
SECURITY AGREEMENT Recorded Oct 3, 2005
From: EMISPHERE TECHNOLOGIES, INC.
To: MHR INSTITUTIONAL PARTNERS IIA LP
Reel/Frame 016617/0145 →